INS and type 1 diabetes mellitus: Furthermore, glucagon-like peptide-1 (GLP-1) receptor agonists, typically used in type 2 diabetes, are being studied for their potential to enhance insulin secretion and provide protective effects on beta cells in T1D patients [42].